In Brief: Bard
This article was originally published in The Gray Sheet
Bard: Medical division commences marketing in the North American hospital and home health markets ProCyte's line of acute and extended-care wound care products, including Iamin hydrating gel, Iamin wound cleanser and OsmoCyte pillow wound dressings. Redmond, Washington-based ProCyte reported in August at the Medical Investments Northwest conference in Seattle that the firm was actively seeking a marketing partner for its Iamin wound care gel ("The Gray Sheet" Aug. 25, I&W-6), which has been marketed by ProCyte since July 1996. The hydrogel is indicated for treating diabetic, venous or mixed etilogy leg ulcers, pressure sores, first and second-degree burns, donor sites and surgical wounds. OsmoCyte is indicated for the exudation of an array of dermal wounds. Terms of the deal call for Bard to purchase on an annual basis a minimum amount of devices from ProCyte, which retains rights to sell the products in the North American dermatology and cosmetic surgery markets...
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.